| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/10/2005 | US20050032812 Administering a dopamine D1, D2, D3, and D4 receptor agonist such as pramipexole or talipexol; for treating overweight or obesity or type 2 diabetes |
| 02/10/2005 | US20050032809 5-HT receptor ligands and uses thereof |
| 02/10/2005 | US20050032806 Method for treating anhedonia using dopamine agonists |
| 02/10/2005 | US20050032801 Compositions containing a ruthenium(III) complex and a heterocycle |
| 02/10/2005 | US20050032784 administering mixtures of carriers or excipients and angiotensin-converting-enzyme inhibitors, calcium channel blockers anddiuretic, as hypotensive agents |
| 02/10/2005 | US20050032783 Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 02/10/2005 | US20050032780 Method of treating functional bowel disorders |
| 02/10/2005 | US20050032776 Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 02/10/2005 | US20050032761 Lipid profile modulation |
| 02/10/2005 | US20050032759 administering to humans synergystic mixtures of aromatase inhibitors and epidermal growth factor receptor antagonists as antitumor agents |
| 02/10/2005 | US20050032758 Hormone replacement therapy and depression |
| 02/10/2005 | US20050032753 Substituted phenol compounds useful for anesthesia and sedation |
| 02/10/2005 | US20050032751 Methods for treatment of dermatological conditions |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032731 Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection |
| 02/10/2005 | US20050032725 useful in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous effector T cell response to antigens |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032720 contains misoprostol, a tetracycline (doxycycline), an aminoglycoside (gentamicin), a fluoroquinoline (ciprofloxacin), a lincomycin (clindamycin), a macrolide (clarithromycin), an azalide (azithromycin), and an imidazole (metronidazole) |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032714 immunotherapeutic for therapy and prophylaxis of cancer; reduced duration, less toxicity, and as thus results in improved tolerance |
| 02/10/2005 | US20050032708 up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursors (N-acetyl cysteine); for treating neuropsychiatric disorder like schizophrenia, psychosis, bipolar disorder, manic depression, affective disorder, drug induced psychosis, delirium |
| 02/10/2005 | US20050032702 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 02/10/2005 | US20050032699 Composition of a VEGF antagonist and an anti-proliferative agent |
| 02/10/2005 | US20050032698 includes a divalent cation (zinc chloride) in an amount effective to stabilize the hormone; osteoporosis |
| 02/10/2005 | US20050032696 Muscle transcription factors |
| 02/10/2005 | US20050032693 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 02/10/2005 | US20050032691 Methods for treating glaucoma |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032155 Expression vector comprising nucleotide sequences coding defective receptor protein for use as model in treatment and prevention of convulsive disorders |
| 02/10/2005 | US20050032134 Neoplasm-specific polypeptides and their uses |
| 02/10/2005 | US20050032133 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen |
| 02/10/2005 | US20050032131 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 02/10/2005 | US20050032064 Method and device for identifying substances capable of modulating adipocyte differentiation |
| 02/10/2005 | US20050032062 Methods for the assessment and prognosis of sarcoidosis |
| 02/10/2005 | US20050032039 HIV-specific T-cell induction |
| 02/10/2005 | US20050032038 Methods of identifying anti-viral agents |
| 02/10/2005 | US20050031708 Composition comprising a zeolite compound for treatment of diseases |
| 02/10/2005 | US20050031706 A bismuth containing agent , a non-clay-derived suspending agent; an stabilizer for reducing viscosity change during storage of the formulation and water |
| 02/10/2005 | US20050031704 Tricalcium phosphates, their composites, implants incorporating them, and method for their production |
| 02/10/2005 | US20050031698 Hydroxyapatite/collagen (HAp/Col) nanocomposite; a bioabsorbable capsule capable of enclosing growth factor, DNA enzyme therein |
| 02/10/2005 | US20050031692 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | US20050031688 Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| 02/10/2005 | US20050031687 Enteric-coated proliposomal formulations for poorly water soluble drugs |
| 02/10/2005 | US20050031681 Mixture with a thixotropic gelatine carrier to form gelatin capsules; enhanced the solubility, stability and absorption |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031612 Cytotoxic t lymphocytes; human leukocyte antigen; non-hematopoietic cells; graft versus host disease |
| 02/10/2005 | US20050031609 Compositions for use in treating ige-associated disorders |
| 02/10/2005 | US20050031601 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 02/10/2005 | US20050031597 Cells and improved method for preserving cells |
| 02/10/2005 | US20050031596 Cells and method for preserving cells |
| 02/10/2005 | US20050031595 Ex-vivo expanding a population of stem cells, while inhibiting differentiation of the stem cells using a transition metal compound that chelates copper such as tetraethylenepentamine |
| 02/10/2005 | US20050031588 2'-branched nucleosides and Flaviviridae mutation |
| 02/10/2005 | DE10332487A1 Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen Ambroxol for the treatment of chronic nociceptive pain |
| 02/10/2005 | DE10332486A1 Ambroxol für die Behandlung akuter Schmerzen Ambroxol for the treatment of acute pain |
| 02/10/2005 | DE10330842A1 Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit Hyperproliferation und veränderten Differenzierungszuständen von Fibroblasten Use of inhibitors of enzymes with activities of aminopeptidase N and / or of dipeptidyl peptidase IV and pharmaceutical preparations thereof for the treatment and prevention of dermatological diseases with hyperproliferation and altered differentiation states of fibroblasts |
| 02/10/2005 | CA2534464A1 Benzoxazepine compound |
| 02/10/2005 | CA2534371A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 02/10/2005 | CA2534129A1 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | CA2534075A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2534074A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2534073A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2532883A1 Supplement preparation |
| 02/10/2005 | CA2531279A1 Treatment and preventi0n of cardiovascular events |
| 02/10/2005 | CA2529521A1 Combination of drugs for the treatment of neoplasms |
| 02/10/2005 | CA2528834A1 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 02/10/2005 | CA2527861A1 Alkynyl aryl carboxamides |
| 02/09/2005 | EP1504778A2 Implantable pump for the treatment of obesity |
| 02/09/2005 | EP1504764A1 Treatment of liver fibrosis with antagonists of alpha V beta 6 integrin |
| 02/09/2005 | EP1504758A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504757A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504754A1 Gallocatechin gallate-containing composition |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504118A2 Therapeutic use of selective pde10 inhibitors |
| 02/09/2005 | EP1504027A2 Adipocyte complement related protein zacrp8 |
| 02/09/2005 | EP1504010A1 Vitamin-mitomycin conjugates |
| 02/09/2005 | EP1504004A2 Substituted pyrazolopyrimidines |
| 02/09/2005 | EP1503988A2 Fredericamycin derivatives |
| 02/09/2005 | EP1503801A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503791A2 Methods of therapy for inducing tolerance |
| 02/09/2005 | EP1503787A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 02/09/2005 | EP1503783A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503782A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503769A1 Antibiotic/benzoyl peroxide dispenser |
| 02/09/2005 | EP1503766A2 Compositions and methods for treating emphysema |
| 02/09/2005 | EP1503765A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 02/09/2005 | EP1503763A1 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
| 02/09/2005 | EP1503758A1 Methods of modulating smooth muscle contractility |
| 02/09/2005 | EP1503756A1 Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| 02/09/2005 | EP1503755A1 Zonisamide use in obesity and eating disorders |
| 02/09/2005 | EP1503754A1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1503737A1 Nanoparticulate nystatin formulations |
| 02/09/2005 | EP1503734A2 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
| 02/09/2005 | EP1503731A1 Processes for forming a drug delivery device |
| 02/09/2005 | EP1503714A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/09/2005 | EP1432436A4 Nutrient therapy for immuno-compromised patients |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |